Literature DB >> 21187522

KRAS genotyping as biomarker in colorectal cancer: a comparison of three commercial kits on histologic material.

Aldo Cavallini1, Anna Maria Valentini, Catia Lippolis, Daniela Campanella, Vito Guerra, Maria Lucia Caruso.   

Abstract

BACKGROUND/AIM: The crucial role of KRAS status in new colorectal cancer target therapy raises the issue regarding which testing method to use. This study analysed 112 formalin fixed, paraffin-embedded (FFPE) metastatic tissue samples using three different commercially available kits. PATIENTS AND METHODS: A group of 40 KRAS wild-type (wt), 40 codon 12-mutated and 32 codon-13 mutated samples, previously evaluated by real-time PCR (TheraScreen kit), used as reference method, were analysed by Ampli-set-K-RAS and K-RAS StripAssay kit (herein called kit A and B, respectively) based on two different technologies.
RESULTS: The sensitivity of both kits was 92.5% for wt samples, 100% and 95.0% for kit A and B, respectively for samples mutated in codon 12. The specificity was 100% for both kits for all groups of samples. After a minor modification of the kit A method, its specificity reached 100%.
CONCLUSION: of low cost and easy to use, kit A may be suitable for use in a routine diagnostic setting.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21187522

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  8 in total

Review 1.  Current companion diagnostics in advanced colorectal cancer; getting a bigger and better piece of the pie.

Authors:  Jonathan M Loree; Scott Kopetz; Kanwal P S Raghav
Journal:  J Gastrointest Oncol       Date:  2017-02

Review 2.  Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology.

Authors:  Antonia R Sepulveda; Stanley R Hamilton; Carmen J Allegra; Wayne Grody; Allison M Cushman-Vokoun; William K Funkhouser; Scott E Kopetz; Christopher Lieu; Noralane M Lindor; Bruce D Minsky; Federico A Monzon; Daniel J Sargent; Veena M Singh; Joseph Willis; Jennifer Clark; Carol Colasacco; R Bryan Rumble; Robyn Temple-Smolkin; Christina B Ventura; Jan A Nowak
Journal:  J Mol Diagn       Date:  2017-02-06       Impact factor: 5.568

3.  Molecular Biomarkers for the Evaluation of Colorectal Cancer.

Authors:  Antonia R Sepulveda; Stanley R Hamilton; Carmen J Allegra; Wayne Grody; Allison M Cushman-Vokoun; William K Funkhouser; Scott E Kopetz; Christopher Lieu; Noralane M Lindor; Bruce D Minsky; Federico A Monzon; Daniel J Sargent; Veena M Singh; Joseph Willis; Jennifer Clark; Carol Colasacco; R Bryan Rumble; Robyn Temple-Smolkin; Christina B Ventura; Jan A Nowak
Journal:  Am J Clin Pathol       Date:  2017-02-03       Impact factor: 2.493

4.  A genetic database can be utilized to identify potential biomarkers for biphenotypic hepatocellular carcinoma-cholangiocarcinoma.

Authors:  Shaffer R S Mok; Sachin Mohan; Navjot Grewal; Adam B Elfant; Thomas A Judge
Journal:  J Gastrointest Oncol       Date:  2016-08

5.  Eprobe-mediated screening system for somatic mutations in the KRAS locus.

Authors:  Jun Atsumi; Takeshi Hanami; Yasuaki Enokida; Hiroomi Ogawa; Diane Delobel; Yasumasa Mitani; Yasumasa Kimura; Takahiro Soma; Michihira Tagami; Yoshiaki Takase; Tatsuo Ichihara; Izumi Takeyoshi; Kengo Usui; Yoshihide Hayashizaki; Kimihiro Shimizu
Journal:  Oncol Rep       Date:  2015-03-30       Impact factor: 3.906

6.  KRAS mutation analysis by PCR: a comparison of two methods.

Authors:  Louise Bolton; Anne Reiman; Katie Lucas; Judith Timms; Ian A Cree
Journal:  PLoS One       Date:  2015-01-08       Impact factor: 3.240

7.  RAS-expanded Mutations and HER2 Expression in Metastatic Colorectal Cancer: A New Step of Precision Medicine.

Authors:  Anna M Valentini; Elisabetta Cavalcanti; Marianna Di Maggio; Maria L Caruso
Journal:  Appl Immunohistochem Mol Morphol       Date:  2018-09

8.  Detection of low-abundance KRAS mutations in colorectal cancer using microfluidic capillary electrophoresis-based restriction fragment length polymorphism method with optimized assay conditions.

Authors:  Huidan Zhang; Jin Song; Hui Ren; Zhangrun Xu; Xiaonan Wang; Lianfeng Shan; Jin Fang
Journal:  PLoS One       Date:  2013-01-23       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.